RAAS blockade with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) has been reported as beneficial for disease outcome in AMI patients via preventing/reversing endothelial dysfunction and atherosclerosis (64). Here, ACE is linked to endothelial dysfunction.